Lipid-lowering agents and hepatotoxicity.
| Autor: | Demyen M; Rutgers New Jersey Medical School, Newark, New Jersey 07103, USA., Alkhalloufi K, Pyrsopoulos NT |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Clinics in liver disease [Clin Liver Dis] 2013 Nov; Vol. 17 (4), pp. 699-714, x. |
| DOI: | 10.1016/j.cld.2013.07.016 |
| Abstrakt: | Lipid-lowering therapy is increasingly being used in patients for a variety of diseases, the most important being secondary prevention of cardiovascular disease. Many lipid-lowering drugs carry side effects that include elevations in hepatic function tests and liver toxicity. In many cases, these drugs are not prescribed or they are underprescribed because of fears of injury to the liver. This article attempts to review key trials with respect to the hepatotoxicity of these drugs. Recommendations are also provided with respect to the selection of low-risk patients and strategies to lower the risk of hepatotoxicity when prescribing these medications. (Copyright © 2013 Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|